Möchten Sie immer auf dem neuesten Stand bleiben?

- ZEJULA is the only PARP inhibitor approved as monotherapy for all-comer patients in the first-line and recurrent maintenance treatment settings regardless of biomarker status - ZEJULA was...

SHANGHAI and SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed...

SHANGHAI and SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha...

SHANGHAI and SAN FRANCISCO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that F. Ty Edmondson has been...

-- Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT -- -- Recent highlights include successful ZEJULA and Optune commercial launches, NMPA approval for Optune, two highly strategic...

SHANGHAI and SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the Center for Drug...

-- Company to host Conference Call and Webcast on August 13, 2020 at 8:00 a.m. ET -- SHANGHAI and SAN FRANCISCO, July 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative...

China NMPA acceptance of NDA follows recent U.S. FDA approval for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including...

Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China Turning Point to Receive $25 Million Upfront, Potential for Future Milestones of up to $151 Million and...

- The NORA study meets all primary and secondary endpoints - Largest randomized clinical trial (RCT) in ovarian cancer ever conducted in China   - Individualized starting dose regimen shown to...